lilly cares tirzepatide releases Zepbound® (tirzepatide) single-dose vials, expanding supply and access for adults living with obesity Eli Lilly raises price of

Semaglutide is contraindicated in people with a personal or family history of medullary thyroid carcinoma, MEN 2 syndrome, type 1 diabetes, and during pregnancy

Pharmacokinetics and safety of PC-SOD, a lecithinized recombinant superoxide dismutase, in healthy Chinese subjects: A phase 1, randomized, placebo-controlled, dose-escalation study

The average weight loss achieved in the Semaglutide FDA study for weight loss was almost 15% of the initial body weight but it is not unusual to see a patient lose 20% of their body weight of the course of the treatment

NICE guidance does not recommend aromatase inhibitors for treating erectile dysfunction